Multi-Phase Based Signature and Cancer Management: An Insight in Embryo, Brain Tumor, Leukemia, and Von Hippel Lindau Syndrome

• Parvin Mehdipour

  Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, 14155-6447, Iran

It has initiated the multi-phase (MPh) phenomen through the cell cycle machinery, and is an icon related to the novel cell cycle M.Ph, characteristics in variety of neoplastic disorders, including cancer.

Cell cycle governs the whole cell based machinery, initiation, progression, and therapeutic platforms in the neoplastic disorders. Differentiation between benign and malignant cells relies on the functional data within the cell cycle domain. Cancer initiation, progressive manner and therapeutic sphere are also dictated by cell cycle.

Proliferation and growth play key role in initiation and develoment of tumors, including benign and malignant cells. The cell cycle’s checkpoints are restrictively under the cell cycle control. As the matter of fact, it was trusted that there is no return through the routine cell cycling and it was characterized as an everlasting forward cycling manner. But this fact has been revolutionized through the presence of Mosaic multi-phase (M.Ph) based at single cell level. The programmed checkpoints control the transition of phases through the related barriers. Therefore, balancing the carcinogenic processes is capable to control progression, facilitate and guarantee the most effective and personalized/ target based therapy

The multi-phase based strategy has been also performed in the circulating embryonic, fetal chorionic sample (CVS), chronic myeloblastic leukemia and Von Hippel lindau (VHL) syndrome,

Conclusively, early predictive/prognostic value of MPh provides a reliable, personalized diagnostic and diverse target-based therapeutic platforms in different medical complications.

Mehdipour P. Evolutionary Hypothesis in Cell Cycle of Breast Cancer Patients: Mosaic Phases in Single Cancer Cells. Journal of Cancer Research Updates 2022; 11: 43-53.

https://doi.org/10.30683/1929-2279.2022.11.07

Mehdipour P. Predisposing, preventive, predictive cancer marker kit (3xPCM) (International Application No.: PCT/IB2014/065072) 2006. Patent ID:WO 2016/05529A1

Belanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D. Functional Promoter SNPs in Cell Cycle Checkpoint Genes. Human Molecular Genetics 2005; 14: 2641- 8.

https://doi.org/10.1093/hmg/ddi298

Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clinical Cancer Research 2014; 20: 3379-3383.

https://doi.org/10.1158/1078-0432.CCR-13-1551

Dalton S.Linking the cell cycle to cell fate decisions. Trends in Cell Biology 2015; 25: 592-600.

https://doi.org/10.1016/j.tcb.2015.07.007

Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D. Genome-wide association study identifies five new BC susceptibility loci. Nature Genetics 2010; 42: 504-507.

https://doi.org/10.1038/ng.586

Siegel PM, Hardy WR, Muller WJ. Mammary gland neoplasia: insights from transgenic mouse models. Bioessays 2000; 22: 554-563.

https://doi.org/10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A

Salmon ES, Sartorelli AC. Cancer Chemotherapy. In: Katzung. BG, editor. Basic & Clinical Phamacology, Appleton & Lange. UK 1998; 881-915.

Santamaria D, Barriere, C, Cerqueira, A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448: 811-815.

https://doi.org/10.1038/nature06046

Schwanitz G, Raff R. Application of specific cytologic, cytogenetic and molecular-cytogenetic techniques for the characterization of solid tumors. Annales Academiae Medicae Bialostocensis 2005; 50: 91-96.

Ghavamzadeh A, Alimoghaddam K, Mehdipour P, Sharifian R, Schwanitz G, Shamshiri AR. Transformation of chronic myelogeneous leukemia to multiple myeloma: a case report. Acta Medica Iranica 2003; 41(1): 45-49.

Cresspigio J, Berbel LCL, Dias MA, Berbel RF, Pereira SS, Pignatelli D, Mazzuco TL. Von hippel lindau disease. A single gene, several hereditary tumors. J Endocrinol Inves 2018; 41(1): 21-31.

https://doi.org/10.1007/s40618-017-0683-1

Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, et al. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 2001; 81: 573-9.

https://doi.org/10.1038/labinvest.3780266

Gonzalez-Gomez PB, MJ. Lomas J. Arjona D. Alonso ME. Amiñoso C. Lopez-Marin I. Anselmo N.P. Sarasa J.L. Gutierrez, M. Casartelli, C. Rey JA. Aberrant methylation of multiple genes in neuroblastic tumours; and relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 2003; 39: 1478-85.

https://doi.org/10.1016/S0959-8049(03)00312-5

Mehdipour P, Karami F, Javan F, Mehrazin M. Linking ATM promoter methylation to cell cycle PE in brain tumor patients: cellular molecular triangle correlation in ATM territory. Molecular Neurobiology 2015; 52: 293-302.

https://doi.org/10.1007/s12035-014-8864-9

Knudson AG. Mutation and cancer: statistical study of retinoblastoma.Proceedings of the National Academy of Sciences 1971; 68: 820-823.

https://doi.org/10.1073/pnas.68.4.820

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.